drugset / Trial / NCT05256446

AMG 701 Expanded Access Program

NCT05256446 ↗

Expanded access No longer available Amgen

Summary

Expanded access requests for AMG 701 may be considered for adult patients with relapsed and/or refractory multiple myeloma whose disease is in partial response or better after AMG 420 therapy. To request access, use Responsible Party contact information provided in this record.

Timeline

Start
—
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Background pavurutamab Protein / enzyme biologic — —

Indications

No indication recorded.